Associate Director of the Cancer Care Equity Program
Dana-Farber Cancer InstituteASCO 2024, Associate Director, Cancer Care, Cancer Health Disparities, Lung Cancer, Mesothelioma, Thoracic Oncology
Dr. Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She completed her internal medicine residency in Rutgers New Jersey Medical School and fellowship at the Mayo Clinic in Rochester, Minnesota where she was the chief fellow from 2018-2019.
Dr. Florez's clinical interests include targeted therapy for lung cancer and the care of women with lung cancer, including their unique aspects of cancer survivorship. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer.
Apart from her clinical interests in lung cancer, she is also a leading and productive researcher in cancer health disparities, gender and racial discrimination in medical education and medicine. She received many awards including the 2018 Resident of the Year Award by the National Hispanic Medical Association, the Mayo Brothers Distinguished Fellowship award and the 2020 Rising Star award by the LEAD national conference for women in hematology and oncology.
In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine and medical education. The laboratory long-term goals are to create a welcoming environment for medical trainees from historically underrepresented groups in medicine while improving the care of vulnerable populations. Members of the Florez Lab are agents of change.
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer InstituteASCO 2024, Assistant Professor, Lung Cancer, small cell, Thoracic Oncology
Dr. Kehl received his MD from the Feinberg School of Medicine at Northwestern University in 2008. He completed his residency in internal medicine at the Brigham and Women’s Hospital. He received his fellowship training in hematology and medical oncology at the MD Anderson Cancer Center and joined the faculty in the Lowe Center for Thoracic Oncology and the Division of Population Sciences at Dana-Farber in 2017. His research focuses on the impact of healthcare delivery strategies on access to care and outcomes for patients with lung cancer, with a particular focus on analysis of population-level data.
Senior Vice President for Translational Medicine Director
Dana-Farber Cancer InstituteASCO 2024, Lung Cancer, Medical Oncology, Thoracic Oncology, Translational Medicine
Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. He is the Senior Vice President for Translational Medicine and the Scientific Director of the Belfer Center for Applied Cancer Science. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.
ASCO 2024, Hematology - Oncology, Lung Cancer, Thoracic Oncology
Leora Horn, MD, MSc, FRCPC is an Ingram Associate Professor of Cancer Research at Vanderbilt Ingram Cancer Center and Associate Professor of Medicine in the Division of Hematology/Oncology at the Vanderbilt University Medical Center. Dr Horn received her Honors Bachelor of Science and Masters of Science in Pharmacology from the University of Toronto where she also attended medical school and trained in internal medicine and medical oncology. She completed a sub-specialty fellowship in Thoracic Oncology at Vanderbilt University. Her fellowship was funded by an award from the Canadian Association of Medical Oncology.Dr Horn's clinical practice focuses primarily on the care of patients with lung cancer. She is the Clinical Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center. Her research interests include experimental therapeutics and medical education. Her work has been recognized with a VICC Impact award annually for the last eight years for her research contributions made to the Cancer Center.Dr Horn is currently completing a Masters in Health Professional Education through the University of Illinois Chicago and is the Assistant Vice Chairman for Faculty Development in the Department of Medicine where she runs the Schaffner Society to support the careers of clinician educators in the Department of Medicine.Dr Horn is Principal Investigator on several lung cancer clinical trials and educational projects. She has published over 100 papers and book chapters including original papers, reviews and the recent chapter on neoplasms of the Lung in Harrison's Principles of Internal Medicine, 18th edition. She is an active member in the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada.